Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors
April 15 2015 - 7:30AM
Business Wire
Celgene Corporation (NASDAQ:CELG) today announced the election
of Michael W. Bonney to its Board of Directors. Mr. Bonney served
as Chief Executive Officer and a member of the Board of Directors
of Cubist Pharmaceuticals, Inc. from June 2003 until his retirement
on December 31, 2014.
In addition to his tenure as CEO of Cubist, Mr. Bonney’s vast
healthcare experience includes serving as President and Chief
Operating Officer of Cubist from January 2002 to June 2003; holding
various positions of increasing responsibility at Biogen, Inc.,
from 1995 – 2001; and serving in positions of increasing
responsibility in sales, marketing and strategic planning at Zeneca
Pharmaceuticals over an eleven year period.
Mr. Bonney currently serves as a director of Alnylam
Pharmaceuticals, Inc. He is also a trustee of the Tekla complex of
life sciences and healthcare dedicated funds. Mr. Bonney was a
Director of NPS Pharmaceuticals, Inc. from 2005 until its sale to
Shire plc in February 2015. Mr. Bonney received a B.A. in Economics
from Bates College and currently chairs the board of trustees of
Bates College.
“Mike’s extensive leadership and operational experience will
help guide us as we execute our key strategic imperatives,” said
Bob Hugin, Celgene Chairman and Chief Executive Officer. “Celgene
will benefit greatly from Mike’s knowledge and insights on the
increasingly dynamic global healthcare environment.”
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey,
is an integrated global pharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through gene and protein regulation. For more information, please
visit www.celgene.com. Follow Celgene on Twitter
@Celgene, and on Pinterest and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
Celgene
CorporationInvestors:908-673-9628investors@celgene.comorMedia:908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024